摘要
目的研究晚期食管癌应用多西他赛（DOC）与奥沙利铂（L-OHP）联合化疗的疗效与不良反应。方法选取我院肿瘤科于2013年1月~2014年12月收治的晚期食管癌患者82例,随机分为两组：观察组（n=41）采用DOC＋L-OHP化疗,对照组（n=41）采用DOC＋顺铂（DDP）化疗,对比两组的近期疗效、生存情况及不良反应。结果观察组的客观有效率为53.66%,与对照组（43.90%）比较,差异无统计学意义（P〉0.05）;观察组的中位生存时间（MST）及中位进展时间（TTP）为（9.25±2.52）个月和（6.42±1.21）个月,对照组为（8.62±2.35）个月和（5.95±1.17）个月,两组比较差异无统计学意义（P〉0.05）;观察组的临床受益（镇痛减药量≥50%、KPS改善≥20分、体重增加≥7%）依次为41.46%、65.85%、24.39%,均显著高于对照组的19.51%、43.90%、7.32%（P〈0.05）。观察组白细胞减少、血小板减少、恶心呕吐、腹泻发生率为39.02%、7.32%、29.27%、4.88%,显著低于对照组的73.17%、29.27%、78.05%、24.39%（P〈0.05）;观察组神经系统毒性发生率为60.98%,显著高于对照组的14.63%（P〈0.05）。结论 DOC联合L-OHP治疗晚期食管癌疗效确切、不良反应能够耐受,值得推广应用。
Objective To investigate the efficacy and adverse reactions of oxaliplatin（L-OHP） combined with docetaxel（DOC） chemotherapy in the treatment of advanced esophageal cancer. Methods 82 patients with advanced esophageal cancer in our hospital were selected in this study. All patients were randomly divided into two groups. The observation group（n=41） had chemotherapy with DOC plus L-OHP and the control group（n=41） with DOC plus cisplatin（DDP）. The short-term curative effects, survival and adverse reactions were compared between the two groups. Results The objective efficiency was 53.66% in observation group and 43.90% in control group, without statistically significant difference between the two groups（P〉0.05）. The median survival time（MST） and the median time to progression（TTP） in the observation group were respectively（9.25±2.52） months and（6.42±1.21） months, and were respectively（8.62±2.35） months and（5.95±1.17） months in the control group. There were also no statistical differences between the two groups（P〉0.05）. However, in the observation group, the clinical benefit was respectively 41.46%, 65.85% and 24.39% for analgesic reduced dose more than or equal to 50%, an improvement in KPS more than or equal to 20 points, and those weight gain more than or equal to 7%, all significantly higher than those of the control group of 19.51%, 43.90% and 7.32%（P〈0.05）. The incidence rate of leukopenia, thrombocytopenia, nausea vomiting, and diarrhea was 39.02%, 7.32%, 29.27% and 4.88% in observation group, all significantly lower than that in the control group of 73.17%, 29.27%, 78.05% and 24.39% respectively（P〈0.05）. Yet the observation group had significantly higher occurrence rate of nervous system toxicity than that of the control group（60.98% vs.14.63%）（P〈0.05）. Conclusion DOC combined with L-OHP was effective in the treatment of advanced esophageal cancer, and adverse reactions could be tolerated Therefore, the chemotherapy of DOC plus L-OHP could be popularly applied in clinic.
出处
《肿瘤药学》
CAS
2016年第5期361-365,共5页
Anti-Tumor Pharmacy
关键词
食管癌
晚期
奥沙利铂
顺铂
多西他赛
临床疗效
不良反应
Esophageal cancer
Advanced
Asha Leigh Per
Cisplatin
Docetaxel
Clinical efficacy
Adverse reaction
